{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:55Z","timestamp":1786982755486,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T00:00:00Z","timestamp":1353974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Drug Investigation"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40261-012-0032-2","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T18:06:17Z","timestamp":1355940377000},"page":"45-54","source":"Crossref","is-referenced-by-count":16,"title":["Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions"],"prefix":"10.1007","volume":"33","author":[{"given":"Manuel","family":"Mart\u00ednez-Sell\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Datino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Figueiras-Graillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joubert G.","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","volume":"58","author":"PJ Failkow","year":"1981","unstructured":"Failkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916\u20139.","journal-title":"Blood"},{"key":"32_CR2","first-page":"520","volume":"89","author":"G Birgeg\u00e5rd","year":"2004","unstructured":"Birgeg\u00e5rd G, Bj\u00f6rkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520\u20137.","journal-title":"Haematologica"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1097-0142(19880315)61:6<1207::AID-CNCR2820610625>3.0.CO;2-4","volume":"61","author":"JJ Lahuerta-Palacios","year":"1988","unstructured":"Lahuerta-Palacios JJ, Bornstein R, Fern\u00e1ndez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer. 1988;61:1207\u201312.","journal-title":"Cancer"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clinthera.2009.02.008","volume":"31","author":"PE Petrides","year":"2009","unstructured":"Petrides PE, Gisslinger H, Steurer M, et al. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther. 2009;31:386\u201398.","journal-title":"Clin Ther"},{"key":"32_CR5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjp.0706341","volume":"146","author":"G Wang","year":"2005","unstructured":"Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005;146:324\u201332.","journal-title":"Br J Pharmacol"},{"key":"32_CR6","first-page":"789","volume":"60","author":"M Kot","year":"2008","unstructured":"Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2008;60:789\u201397.","journal-title":"Pharmacol Rep"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","volume":"97","author":"EC Storen","year":"2001","unstructured":"Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863\u20136.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"32_CR9","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","volume":"16","author":"E Bischoff","year":"2004","unstructured":"Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl. 1):S11\u20134.","journal-title":"Int J Impot Res"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","volume":"2","author":"PP Rickham","year":"1964","unstructured":"Rickham PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 1964;2:177.","journal-title":"Br Med J"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2307\/2556170","volume":"28","author":"GG Koch","year":"1972","unstructured":"Koch GG. The use of non-parametric methods in the statistical analysis of the two period change-over design. Biometrics. 1972;28:577\u201384.","journal-title":"Biometrics"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1542-474X.2005.05604.x","volume":"10","author":"A Dogan","year":"2005","unstructured":"Dogan A, Tunc E, Varol E, et al. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann Noninvasive Electrocardiol. 2005;10:134\u201341.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"32_CR13","unstructured":"Xagrid\u00ae Summary of Product Characteristics (online). Available from URL http:\/\/www.medicines.org.uk\/emc\/document.aspx?documentId=15737 . Accessed 7 Nov 2011."},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-007-9014-5","volume":"12","author":"JT Parissis","year":"2007","unstructured":"Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007;12:149\u201356.","journal-title":"Heart Fail Rev"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.HYP.38.2.227","volume":"38","author":"A Mahmud","year":"2001","unstructured":"Mahmud A, Feely J. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Hypertension. 2001;38:227\u201331.","journal-title":"Hypertension"},{"key":"32_CR16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.21.5.437.34502","volume":"21","author":"R Ammar","year":"2001","unstructured":"Ammar R, Song JC, Kluger J, White CM. Evaluation of electrocardiographic and hemodynamic effects of caffeine with acute dosing in healthy volunteers. Pharmacotherapy. 2001;21:437\u201342.","journal-title":"Pharmacotherapy"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0002-9149(02)02725-X","volume":"90","author":"HP Sondermeijer","year":"2002","unstructured":"Sondermeijer HP, van Marle AG, Kamen P, et al. Acute effects of caffeine on heart rate variability. Am J Cardiol. 2002;90:906\u20137.","journal-title":"Am J Cardiol"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/hy1201.098767","volume":"38","author":"C Vlachopoulos","year":"2001","unstructured":"Vlachopoulos C, Hirata K, O\u2019Rourke MF. Pressure-altering agents affect central aortic pressures more than is apparent from upper limb measurements in hypertensive patients: the role of arterial wave reflections. Hypertension. 2001;38:1456\u201360.","journal-title":"Hypertension"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1161\/01.CIR.0000046228.97025.3A","volume":"106","author":"R Corti","year":"2002","unstructured":"Corti R, Binggeli C, Sudano I, et al. Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation. 2002;106:2935\u201340.","journal-title":"Circulation"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01857602","volume":"19","author":"PJ Green","year":"1996","unstructured":"Green PJ, Suls J. The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. J Behav Med. 1996;19:111\u201328.","journal-title":"J Behav Med"},{"key":"32_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/140349489602400209","volume":"24","author":"ML L\u00f8chen","year":"1996","unstructured":"L\u00f8chen ML, Rasmussen K. Palpitations and lifestyle: impact of depression and self-rated health. The Nordland Health Study. Scand J Soc Med. 1996;24:140\u20134.","journal-title":"Scand J Soc Med"},{"key":"32_CR22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ije\/14.2.239","volume":"14","author":"MJ Shirlow","year":"1985","unstructured":"Shirlow MJ, Mathers CD. A study of caffeine consumption and symptoms; indigestion, palpitations, tremor, headache and insomnia. Int J Epidemiol. 1985;14:239\u201348.","journal-title":"Int J Epidemiol"},{"key":"32_CR23","unstructured":"Hasan AS, Morton C, Armstrong MA, et al. Coffee, caffeine, and risk of hospitalization for arrhythmias (abstract no. P461 plus poster). 50th EPI\/NPAM, San Francisco. 2010."},{"key":"32_CR24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200666010-00006","volume":"66","author":"AJ Wagstaff","year":"2006","unstructured":"Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs. 2006;66:111\u201331.","journal-title":"Drugs"},{"key":"32_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/occmed\/kql107","volume":"57","author":"C Ihlebaek","year":"2007","unstructured":"Ihlebaek C, Brage S, Eriksen HR. Health complaints and sickness absence in Norway, 1996\u20132003. Occup Med (Lond). 2007;57:43\u20139.","journal-title":"Occup Med (Lond)"},{"key":"32_CR26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5414\/CPP46574","volume":"46","author":"L Almeida","year":"2008","unstructured":"Almeida L, Coelho R, Albino-Teixeira A, et al. Adverse non-drug-related complaints by healthy volunteers in Phase I studies compared to the healthy general population. Int J Clin Pharmacol Ther. 2008;46:574\u201383.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"32_CR27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/14034948020300010701","volume":"30","author":"C Ihlebaek","year":"2002","unstructured":"Ihlebaek C, Eriksen HR, Ursin H. Prevalence of subjective health complaints (SHC) in Norway. Scand J Public Health. 2002;30:20\u20139.","journal-title":"Scand J Public Health"},{"key":"32_CR28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.amjcard.2010.12.047","volume":"107","author":"E Vall\u00e8s","year":"2011","unstructured":"Vall\u00e8s E, Mart\u00ed-Almor J, Bazan V, et al. Diagnostic and prognostic value of electrophysiologic study in patients with nondocumented palpitations. Am J Cardiol. 2011;107:1333\u20137.","journal-title":"Am J Cardiol."},{"key":"32_CR29","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.leukres.2011.07.031","volume":"35","author":"C Besses","year":"2011","unstructured":"Besses C, Mart\u00ednez-Sell\u00e9s M. Anagrelide and cardiovascular events. Much ado about nothing? Leuk Res. 2011;35:1543\u20134.","journal-title":"Leuk Res"},{"key":"32_CR30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/hrt.79.5.468","volume":"79","author":"CA O\u2019Sullivan","year":"1998","unstructured":"O\u2019Sullivan CA, Henein MY, Sutton R, et al. Abnormal ventricular activation and repolarisation during dobutamine stress echocardiography in coronary artery disease. Heart. 1998;79:468\u201373.","journal-title":"Heart"},{"key":"32_CR31","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/CIRCULATIONAHA.105.600445","volume":"113","author":"H Vyas","year":"2006","unstructured":"Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation. 2006;113:1385\u201392.","journal-title":"Circulation"},{"key":"32_CR32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-143-4-200508160-00020","volume":"143","author":"PJ Engel","year":"2005","unstructured":"Engel PJ, Johnson H, Baughman RP, et al. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med. 2005;143:311\u20133.","journal-title":"Ann Intern Med"},{"key":"32_CR33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2459\/JCM.0b013e32832b7f08","volume":"10","author":"R Proietti","year":"2009","unstructured":"Proietti R, Rognoni A, Ardizzone F, et al. Atypical Takotsubo syndrome during anagrelide therapy. J Cardiovasc Med (Hagerstown). 2009;10:546\u20139.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"32_CR34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00277-008-0451-6","volume":"87","author":"RS Wong","year":"2008","unstructured":"Wong RS, Lam LW, Cheng G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Ann Hematol. 2008;87:683\u20134.","journal-title":"Ann Hematol"},{"key":"32_CR35","first-page":"1394","volume":"89","author":"DJ Jurgens","year":"2004","unstructured":"Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica. 2004;89:1394\u20135.","journal-title":"Haematologica"},{"key":"32_CR36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1592\/phco.20.15.1224.34591","volume":"20","author":"CW James","year":"2000","unstructured":"James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy. 2000;20:1224\u20137.","journal-title":"Pharmacotherapy"},{"key":"32_CR37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/17482940701613653","volume":"10","author":"R Prieto","year":"2008","unstructured":"Prieto R, Martinez-Selles M, Fernandez-Aviles F. Essential thrombocytemia and acute coronary syndrome: clinical profile and association with other thromboembolic events. Acute Card Care. 2008;10:116\u201320.","journal-title":"Acute Card Care"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0032-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0032-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T22:48:16Z","timestamp":1595112496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0032-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,27]]}}}